Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Illumina

Stocks Fall Back after Monday’s Tech-Led Rally

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.36%. Stocks this morning are moderately lower as technology stocks...

Barchart

Stocks Rise on Dovish Fed Comment

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.36%. Stocks this morning are mildly higher, with the S&P...

Barchart

Icahn Targets Illumina's Legacy Directors Removal

In a daring move, visionary investor Icahn seeks to oust Illumina's old guard, asserting fresh energy is needed in a vibrant, change-chasing letter.

Top News

AI will live up to the hype and more unicorns will lose their horns: 10 health care predictions for 2024 from top investors

Top health care investors Bob Kocher and Bryan Roberts share their annual predictions for the sector–and how last year's list panned out.

Fortune

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators

The Independent UK

Inside Illumina’s bruising proxy battle with billionaire activist investor Carl Icahn

Illumina’s contentious acquisition of cancer test maker Grail brought billionaire Carl Icahn to the company’s doorstep.

Fortune

Read news from The Economist, FT, and more,
with one subscription

EU fines US firm Illumina $475 million for jumping gun on buying cancer-screening company Grail

The European Union has slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc’s antitrust watchdog

The Independent UK

Cancer vaccines are already a reality. Here's what you need to know about the cutting-edge technology that could usher in an era of personalized medicine

The concept may seem torn from the plot of some futuristic sci-fi movie, or from the pages of some decades-old utopian novel far ahead of its time. But such wonders of science exist today.

Fortune

Illumina’s Sudden CEO Exit Is Just One of Many Problems Facing DNA Company

The sudden resignation of Francis deSouza raises questions about the firm’s future after its proxy fight with Carl Icahn.

Businessweek

Primate genome study reveals evolutionary traits, human uniqueness and disease mutations

CCMB team, along with international scientists, conducted genome sequencing of 809 individuals from 233 primate species, covering nearly half of all existing primate species on earth

The Hindu

Studying Primates Sheds Light On Causes Of Common Diseases

Scientists mapped the DNA of over 800 individuals from 233 primate species.

Zenger

Carl Icahn’s activist play plays into the hands of Lina Khan and EU regulators

Every company with acquisition plans in the U.S. and Europe should be concerned about the FTC partnering with EU regulators to sink the Illumina-Grail deal.

Fortune

DNA sequencing platform hit by serious security flaws

One of the two vulnerabilities discovered carries a 10/10 severity score.

TechRadar

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Backlog in NHS genome service leaves families facing long wait for results

Exclusive: Experts say delays of more than a year risk children not getting relevant treatments or support

Fortune

It takes an average of 8 years for a rare disease patient to get diagnosed. Why is it so hard to get life-altering genetic testing in the U.S.?

An increasingly inexpensive genetic test stands in the way of a diagnosis for many rare disease patients, who are as common as one in 10 worldwide.

Fortune

Cancer vaccines are already a reality—but your doctor might not tell you about them unless you ask

“Patients need to advocate for themselves."

Fortune

ChatGPT shows that the A.I. revolution has arrived. We’re not ready

Even more than social media, generative A.I. could disrupt business models and society itself. It's time to ask the tough questions.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

A frozen capital market and an insurance premium shock: 10 health care predictions for 2023 from top investors

Distressed deals, inflation in insurance premiums, and restrictions on transgender treatments. Here's what the health care sector will look like in 2023, according to top investors.

The Guardian - UK

Small wonder: big DNA advances loom at university startup Oxford Nanopore

Company spun out of Oxford University makes DNA and RNA sequencing devices to identify viruses and variants

Benzinga

Looking At Illumina's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Illumina. Looking at options history for Illumina (NASDAQ:ILMN) we detected 26 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022

Upgrades

Axios

DNA sequencing is getting cheaper as competition in the industry heats up

Sequencing behemoth Illumina unveiled a new line of instruments today.

Benzinga

What Are Whales Doing With Illumina

Someone with a lot of money to spend has taken a bullish stance on Illumina (NASDAQ:ILMN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022

Upgrades

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.